John Glenn - Iradimed Chief Officer
| IRMD Stock | USD 53.39 0.16 0.30% |
Insider
John Glenn is Chief Officer of Iradimed Co
| Age | 62 |
| Address | 1025 Willa Springs Drive, Winter Springs, FL, United States, 32708 |
| Phone | 407 677 8022 |
| Web | https://www.iradimed.com |
John Glenn Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Glenn against Iradimed stock is an integral part of due diligence when investing in Iradimed. John Glenn insider activity provides valuable insight into whether Iradimed is net buyers or sellers over its current business cycle. Note, Iradimed insiders must abide by specific rules, including filing SEC forms every time they buy or sell Iradimed'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Glenn over six months ago Disposition of 5795 shares by John Glenn of Iradimed subject to Rule 16b-3 |
Iradimed Management Efficiency
The company has return on total asset (ROA) of 0.1467 % which means that it generated a profit of $0.1467 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2358 %, meaning that it created $0.2358 on every $100 dollars invested by stockholders. Iradimed's management efficiency ratios could be used to measure how well Iradimed manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to 0.17. In addition to that, Return On Capital Employed is expected to decline to 0.24. At present, Iradimed's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 2.6 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | INSIDER Age | ||
| Andre Marquette | Neuropace | N/A | |
| Anne Nunes | Anika Therapeutics | 54 | |
| Leana Wen | Glaukos Corp | 37 | |
| Mark Quick | Orthofix Medical | N/A | |
| L Katz | Glaukos Corp | N/A | |
| Diana Scherer | Glaukos Corp | N/A | |
| Chi Nguyen | Neuropace | 47 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Bart Bracy | Anika Therapeutics | N/A | |
| Denice Torres | Glaukos Corp | 60 | |
| Ehab Esmail | Orthofix Medical | 52 | |
| Mark Saxton | Neuropace | 59 | |
| Lisa Paul | Pulmonx Corp | 60 | |
| Sam Park | Sight Sciences | 63 | |
| John Liu | Sight Sciences | N/A | |
| Lindsey Little | LivaNova PLC | N/A | |
| McAlister Marshall | Integer Holdings Corp | 51 | |
| Jesse Selnick | Sight Sciences | N/A | |
| Barbara Schwarzentraub | CONMED | 53 | |
| John McKune | Pulmonx Corp | 48 | |
| Jeremy Hayden | Sight Sciences | 54 | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 |
Iradimed Leadership Team
Elected by the shareholders, the Iradimed's board of directors comprises two types of representatives: Iradimed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iradimed. The board's role is to monitor Iradimed's management team and ensure that shareholders' interests are well served. Iradimed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iradimed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Randy Waddell, Vice Marketing | ||
| Roger Susi, Founder, CEO and President and Director | ||
| Lynn Neuhardt, Vice Development | ||
| Chris Williamson, Executive Technology | ||
| Matt Garner, Controller | ||
| Steve Kachelmeyer, Vice Assurance | ||
| John Glenn, Chief Officer |
Iradimed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Iradimed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 623.15 M | ||||
| Shares Outstanding | 12.67 M | ||||
| Shares Owned By Insiders | 36.97 % | ||||
| Shares Owned By Institutions | 57.01 % | ||||
| Number Of Shares Shorted | 80.8 K | ||||
| Price To Earning | 28.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0) | Dividend Share 0.45 | Earnings Share 1.46 | Revenue Per Share 5.635 | Quarterly Revenue Growth 0.11 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.